ecrin-mdr-crcClinical2020IPD Sharing (as of September 2023): NoSolid TumorColorectal NeoplasmsAdvanced Solid TumorOvarian NeoplasmsLymphomaAdvanced LymphomaSolid TumorColorectal NeoplasmsAdvanced Solid TumorOvarian NeoplasmsLymphomaAdvanced LymphomaInterventionalhttps://newmdr.ecrin.org/Study/2356224United States11PembrolizumabAdvanced TumorMicrosatellite stable colorectalSTING agonistStimulator of interferon genesB-Cell LymphomasMicrosatellite instable colorectalECRIN MDRActive, not recruitingfalseStudy of SNX281 in Subjects With Advanced Solid Tumors and LymphomaThis clinical trial is evaluating a drug called SNX281 given by itself and in combination with pembrolizumab in participants with advanced solid tumors and lymphoma. The main goals of this study are to: * Find the recommended dose of SNX281 that can be given to participants safely alone and in combination with pembrolizumab. * Learn more about the side effects and safety profile of SNX281 alone and in combination with pembrolizumab * Learn more about pharmacological characteristics of SNX281 alone and in combination with pembrolizumab * Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab2020-11-152356224NCT04609579